← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...
HomeStocksOGNRevenue History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

Organon & Co. (OGN) Revenue History

Annual and quarterly revenue from 2018 to 2025

TTM Revenue
$6.22B
vs. $6.40B LY
YoY Growth
-5.3%
Declining
Latest Quarter
$1.51B
Q4 2025
QoQ Growth
-5.9%
Declining

Compound Annual Growth Rate (CAGR)

3-Year+0.2%Slow
5-Year-1.0%Declining
10-Year-
Highest Annual Revenue$9.78B (2018)
Highest Quarter$1.78B (Q1 2020)
Revenue per Share$23.84

Loading revenue history...

Revenue Growth Metrics

1-Year Growth
-5.3%
Declining
3-Year CAGR
+0.2%
Slow
5-Year CAGR
-1.0%
Declining
10-Year CAGR
-
TTM vs Prior Year$187.0M (-2.9%)
Revenue per Share$23.84
Peak Annual Revenue$9.78B (2018)

Revenue Breakdown

OGN's revenue distribution by segment and geography

By Geography

Europe And Canada27.5%
UNITED STATES24.6%
Asia Pacific and Japan16.4%
Latin America, Middle East, Russia And Africa16.1%
CHINA13.2%
Other Countries2.1%

Download Historical Data

8 records • Includes OHLCV + Technical Indicators (MA50, MA200, RSI)

Free sign in required to download data

OGN Revenue Analysis (2018–2025)

As of March 2, 2026, Organon & Co. (OGN) generated trailing twelve-month (TTM) revenue of $6.22 billion, reflecting moderate decline in growth of -5.3% year-over-year. The most recent quarter (Q4 2025) recorded $1.51 billion in revenue, down 5.9% sequentially.

Looking at the longer-term picture, OGN's 5-year compound annual growth rate (CAGR) stands at -1.0%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $9.78 billion in 2018.

When compared to Healthcare sector peers including NVS (+8.6% YoY), and SRXH, OGN has underperformed the peer group in terms of revenue growth. Compare OGN vs NVS →

Peer Comparison

Compare OGN's revenue metrics with industry peers

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
OGNCurrent$6.2B-5.3%-1.0%20.7%
NVS$54.8B+8.6%+1.9%31.2%
SRXH$119M---4.9%
Best in groupLowest in group

Historical Revenue Data

Showing 8 of 8 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2025$6.22B-2.9%$3.36B54.1%$1.28B20.7%
2024$6.40B+2.2%$3.71B58.0%$1.49B23.2%
2023$6.26B+1.4%$3.75B59.8%$1.33B21.2%
2022$6.17B-2.1%$3.88B62.8%$1.71B27.6%
2021$6.30B-3.5%$3.92B62.2%$1.92B30.4%
2020$6.53B-16.0%$4.41B67.6%$2.85B43.6%
2019$7.78B-20.5%$5.50B70.8%$3.85B49.5%
2018$9.78B-$5.08B52.0%$2.71B27.7%

See OGN's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is OGN Undervalued?

See our Bear / Base / Bull DCF models and intrinsic value estimates.

View Valuation

Compare OGN vs AGIO

See how OGN stacks up against sector leader Agios Pharmaceuticals, Inc..

Start Comparison

Frequently Asked Questions

Is OGN's revenue growth accelerating or slowing?

OGN revenue declined -5.3% year-over-year, contrasting with the 5-year CAGR of -1.0%. TTM revenue fell to $6.2B. This reverses the prior growth trend.

What is OGN's long-term revenue growth rate?

Organon & Co.'s 5-year revenue CAGR of -1.0% reflects the variable expansion pattern. Current YoY growth of -5.3% is below this long-term average.

How is OGN's revenue distributed by segment?

OGN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.

Revenue Over Time